



Pharmacy Formulary Updates for October 2018

To offer a pharmacy benefit that is clinically appropriate and cost effective, we constantly review how we cover prescription medications. Periodic adjustments are made to meet these goals. With the exception of new-to-market medications, the changes below are reflected in our online Preferred Drug List.

The following is a list of drugs that changed formulary status in October 2018:

Drug Name	Tufts Health Public Plan Formulary
	Tufts Health Direct Formulary
Synagis	MB;PA
Donnatal Elixir	Excluded
doxercalciferol	T2
lidocaine 4% OTC patches	T2;QL
Lidocare 4% OTC patches	T2;QL
malathion 0.5 % lotion	T2
spinosad 0.9% suspension	T2
acyclovir 5% ointment	T2
ciclopirox 1% shampoo	T2
clotrimazole/betamethasone 1%-0.05% lotion	T2
mupirocin 2% cream	T2
fenofibrate 130 mg capsules	T2
ketoconazole 2% foam	T3
Nucort 2% lotion	Excluded
Claravis	T3
desoximetasone 0.25% spray	NC
dorzolamide hydrochloride/timolol maleate PF	T2
Cosopt PF	NC
Braftovi capsules	T2;PA
Mektovi tablets	T2;PA
Doptelet	T3;PA;SP
Fulphila	T2;PA;SP;QL
Benznidazole	T2
Imvexxy	NC
Symtuza	T2
imiquimod 3.75% pump cream	T2;QL

Zyclara 3.75% pump cream

NC;QL

Key:

MB: Medical Benefit

NC: Not covered

NTM: New-to-market

PA: Prior Authorization

QL: Quantity Limitation

SP: Specialty Pharmacy - provided
through CVS/specialty

ST: Step Therapy